cbdMD, Inc.

YCBD
About the company

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. Its cbdMD brand products include oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products.

Country: United StatesPrice: $0.37Market Cap: $5.0M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

4 / 11

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Strongest signal

8 of 12 pass — Graham, Buffett, Lynch +1 more object

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2888 (Top 93.3%)NEUTRALFAILPASSFAILFAILFAILFAILNEUTRALFAILFAILFAILNEUTRALNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-12-19

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-12-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2025-12-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2025-12-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-12-19

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2025-12-19

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-13

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-13

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage67% pass✓ 11✗ 4▾

    8 of 12 pass — Graham, Buffett, Lynch +1 more object

    LT Debt vs Net Current Assets
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest Coverage
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0
    ✓Lynch< 0.33
    Cash - Long-term Debt
    ✗LynchPositive preferred
    LT Debt / Total Assets Change0.00% -> 0.00%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities2.50
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0
    ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDA
    ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.0009; #357/4210 (top 8.5%)
    ✓AsnessTop 30% of eligible cross-section

Where It Falls Short

  • Valuation0% pass✓ 8✗ 20▾

    No clean pass — all 13 investors flag at least one valuation criterion

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio0.5x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value-78.3%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-78.3%, ROC=-157.4%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    Price / Book Value per Share0.5x
    ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
    Valuation Reasonableness
    ✗MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=-32.6%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=0.5x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Price vs. Trailing Low100% of trailing low ($0.37)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization-57.48%; #5128/6340 (top 80.9%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+1.6344; #818/6449 (top 12.7%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share0.65x
    ✓SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+4.1658; #633/5247 (top 12.1%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-47.95%; #3841/4519 (top 85.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-56.96%; #5330/6202 (top 85.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Cash Flow0% pass✓ 1✗ 11▾

    No clean pass — all 10 investors flag at least one cash flow criterion

    Free Cash Flow Proxy$-22.7M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-1.6M
    ✗LynchPositive and growing
    Operating Cash Flow$-1.5M
    ✗PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=-13.94%, ROA=-19.59%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)N/A (negative CFPS)
    ✗Dreman< 8x
    P/E or FCF YieldFCF Yield=-32.6%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive0/10 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-72.2%
    ✗Ackman>= 4%
    Price / FCF per ShareN/A (negative FCF)
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency0/10 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-2.4M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-47.95%; #3841/4519 (top 85.0%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth0% pass✓ 1✗ 12▾

    No clean pass — all 8 investors flag at least one growth criterion

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 9.0% vs Rev: 10.0%
    ✓LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency2/10 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-19.3%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 62.0% -> 62.4%, operating margin -93.1% -> -11.3%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-14.5%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability6% pass✓ 7✗ 28▾

    15 of 16 flag YCBD's profitability — Graham, Buffett, Lynch +12 more

    Positive EPS (10 years)1/11 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)2/11 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-158.6%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)-11.3% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$-22.7M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE-35.2%
    ✗Lynch> 15%
    EBIT / Enterprise Value-78.3%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=-78.3%, ROC=-157.4%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-19.59%
    ✗PiotroskiROA > 0
    ROA Change YoY-34.97% -> -19.59% (delta: +15.38%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=-13.94%, ROA=-19.59%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY61.6% -> 62.4%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue-13.8%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity-35.2%
    ✗Dreman> 12%
    Margin of SafetyP/B=0.5x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-156.9% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency2/10 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue-13.9%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity-35.2%
    ✗Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-93.1% (2023) -> -11.3% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 62.0% -> 62.4%, operating margin -93.1% -> -11.3%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization-57.48%; #5128/6340 (top 80.9%)
    ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+91.84%; #169/3702 (top 4.6%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity-35.17%; #3995/5226 (top 76.4%)
    ✗AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.6576; #5096/5884 (top 86.6%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Verdicts8% pass✓ 1✗ 12▾

    Split decision: 11 FAIL · 4 NEUTRAL · 1 PASS

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #2888•PiotroskiNEUTRAL (F-Score 6)✗DremanFAIL (3/11)✓MungerPASS (2/4)✗PabraiFAIL (1/3)✗AkreFAIL (2/6)✗MarksFAIL (1/5)✗AckmanFAIL (2/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (1/6)✗AsnessFAIL (Rank #1535/2370 (Top 64.8%))✗NeffFAIL (0/6)•SchlossNEUTRAL (4/7)•OshaughnessyNEUTRAL (Not ranked)
  • Efficiency38% pass✓ 4✗ 7▾

    5 of 8 flag YCBD's efficiency — Buffett, Greenblatt, Munger +2 more

    Current Ratio2.50
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-135.6%
    ✗Buffett> 10%
    ROIC - WACC-145.6%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)-157.4%
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.74 -> 2.05
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY1.84x -> 1.84x
    ✓PiotroskiImproved YoY
    Current Assets / Current Liabilities2.50
    ✓Dreman> 1.5
    Return on Invested Capital-27.9%
    ✗Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-196.7%; FY2024: ROIC=-133.4%; FY2025: ROIC=unavailable
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/4 years above 12% (latest -133.4%)
    ✗SleepROIC > 12% in a majority of years

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Consumer Goods
SIC Sector: Chemicals & Pharmaceuticals
Size: Micro Cap($5.0M)
Revenue: $19.2M-1.5% YoY
Net Income: $2.0M+44.8% YoY

Financial Snapshot

Operating Margin-11.3%
Return on Equity-28.2%
Debt / Equity--
Current Ratio2.05
EPS (Diluted)$-1.09

Similar Companies

ULUNILEVER PLC
$142.6B
ECLECOLAB INC.
$86.7B
CLCOLGATE PALMOLIVE CO
$79.2B
ELESTEE LAUDER COMPANIES INC
$40.5B

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-06-30

2025-07-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, capex.

Q3 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q2 FY 2026

2026-01-01 – 2026-03-31

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex.

Q1 · 2025-12-31

2025-10-01 – 2025-12-31

Sources
FY 2025
Sources
  • 10-K · 2025-12-19
FY 2024
Sources
  • 10-K · 2024-12-18
FY 2023
Sources
  • 10-K · 2023-12-22
FY 2022
Sources
  • 10-K · 2022-12-15
FY 2021
Sources
  • 10-K · 2021-12-17
Market Cap$5.0Mcurrent------$9.3Mest.$18.0Mest.$18.6Mest.$7.5Best.$21.6Best.
Revenue$20.9M↑10%$5.6M↑21%$5.6M↑19%$5.0M↓2%$19.2M↓1%$19.5M↓19%$24.2M↓32%$35.4M↓20%$44.5M
Operating Income-$2.9M↓62%-$1.1M↓25%-$800.8K↓65%-$286.3K↓232%-$2.2M↑35%-$3.3M↑85%-$22.5M↑71%-$78.3M↓299%-$19.6M
Net Income-$2.9M↓91%-$1.1M↓26%-$798.0K↓66%-$283.1K↓1976%-$2.0M↑45%-$3.7M↑84%-$22.9M↑67%-$70.1M↓200%-$23.4M
EPS (Diluted)--------$-1.09↑39%$-1.79↑87%$-13.32↓974%$-1.24↓164%$-0.47
Gross Margin57.7%↓6%54.7%↓11%57.7%↓7%59.8%↓10%62.4%↑1%61.6%↓1%62.0%↓2%63.1%↓6%67.4%
Operating Margin-13.9%↓47%-20.4%↓4%-14.2%↓39%-5.7%↓238%-11.3%↑34%-17.0%↑82%-93.1%↑58%-221.1%↓401%-44.1%
ROE-35.2%↓42%———-28.2%↑85%-188.5%↑26%-254.0%↑7%-272.4%↓443%-50.2%
Total Debt$7.3K$7.3K$7.3K----$0↓100%$2.5K↓98%$135.1K↓20%$168.5K
Shareholders' Equity$8.2M↑34%$8.2M↑34%$9.3M↑1295%$9.0M↑406%$7.2M↑268%$2.0M↓78%$9.0M↓65%$25.7M↓45%$46.6M
Current Ratio2.50↑60%2.50↑60%2.82↑350%2.94↑324%2.05↑177%0.74↓57%1.73↓43%3.03↓43%5.28
Debt / Equity0.000.000.00——0.00↓100%0.00↓95%0.01↑45%0.00
Operating Cash Flow-$2.2M-$442.2K↑37%-$722.5K-$812.5K-$1.5M↓312%-$352.8K↑92%-$4.3M↑71%-$15.0M↓6%-$14.1M
Free Cash Flow-$2.4M-$460.2K↑35%-$728.2K-$977.3K-$1.6M↓201%-$542.8K↑88%-$4.6M↑71%-$15.7M↓8%-$14.4M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Consumer Goods

YCBD vs Peers — Financial Grading

Revenue$19.2MBottom 25%
Net Income$2.0MBottom 25%
ROE-28.2%Bottom 25%
D/E—
Op. Margin-11.3%Bottom 25%
Curr. Ratio2.05Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
UNILEVER PLCUL$142.6B$66.21$59.3B$11.1B61.0%1.6817.9%0.792/94/94/71/3F-Score 86/11
ECOLAB INC.ECL$86.7B$309.27$16.1B$2.1B21.2%0.8417.0%1.083/95/93/71/3F-Score 65/11
COLGATE PALMOLIVE COCL$79.2B$99.67$20.4B$2.1B3948.1%147.8916.2%0.832/95/93/71/3F-Score 53/11
ESTEE LAUDER COMPANIES INCEL$40.5B$111.75$14.3B$1.1B-29.3%1.89-5.5%1.302/94/92/70/3F-Score 61/11
CHURCH & DWIGHT CO INC /DE/CHD$26.7B$113.00$6.2B$736.8M18.4%0.5517.4%1.073/97/93/71/3F-Score 74/11
CANON INCCAJPY$25.2B$30.28——————3/91/91/71/3F-Score 75/11
SOMNIGROUP INTERNATIONAL INC.SGI$14.0B$60.76$7.5B$384.1M12.4%1.5110.1%0.831/95/92/71/3F-Score 52/11
INTERPARFUMS INCIPAR$4.3B$133.37$1.5B$168.4M19.1%0.2018.2%2.994/95/96/71/3F-Score 57/11